Archived Monthly Oncology Tumor Boards: Esophageal and Esophagogastric Junction Cancers: Postoperative Therapy in Patients with Residual Disease

Archived Monthly Oncology Tumor Boards: Esophageal and Esophagogastric Junction Cancers: Postoperative Therapy in Patients with Residual Disease is organized by National Comprehensive Cancer Network (NCCN) and will be held from Nov 21, 2022 - Nov 21, 2023.,,Description:,Esophageal cancer patients with residual disease following preoperative chemoradiation and complete resection remain at high risk for recurrence, which is associated with poor prognosis. The components of optimal postoperative management for these patients has not been established in randomized trials. Available evidence for the use of postoperative chemoradiation and postoperative chemotherapy comes from prospective randomized trials involving patients with gastric cancer. Optimal treatment for resectable esophageal/esophagogastric junction (EGJ) cancers requires clinician awareness of current evidence regarding the recurrence and survival rates associated with various combined modality approaches and targeted therapies. Clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies, as well as new indications for existing targeted therapies, become FDA-approved.,,Learning Objectives:,Following this activity, participants should be able to:,• Discuss therapeutic options for the postoperative management of patients with esophageal or esophagogastric junction (EGJ) cancers.,• Review the current evidence for use of nivolumab in patients with completely resected esophageal or EGJ tumors with residual pathologic disease who have received preoperative chemoradiation.,• Describe emerging strategies to optimize postoperative management for patients with completely resected esophageal or EGJ tumors and residual pathologic disease.,• Discuss preoperative treatment strategies for patients with esophageal or EGJ cancers.,,Additional details will be posted as soon as information is available.